Abstract Library

#2895 Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center

Introduction: Well-differentiated Neuroendocrine Pulmonary Tumors (NETp) are morphologically classified as Typical (TC) and Atypical Carcinoid (AC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tanaka H

Authors: Tanaka H, Petrocchi Corassa M, Carioca Freitas H, José de Barros e Silva M, Riechelmann R,

Keywords: Atypical Carcinoid, Typical Carcinoid, Neuroendocrine Pulmonary Tumors,

#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes

Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Taboada R

Authors: Taboada R, Riechelmann R, Mauro C, Barros M, Hubner R,

Keywords: neuroendocrine, everolimus, pneumonitis,

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors

Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors

Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, de Paula C, Donadio M, Barros M, Formiga M,

Keywords: hereditary syndrome, neuroendocrine tumors, germline variants,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,